Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October

Compugen Ltd. (NASDAQ:CGEN) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 1,270,000 shares, a decrease of 18.1% from the October 15th total of 1,550,000 shares. Based on an average trading volume of 225,400 shares, the short-interest ratio is currently 5.6 days.

Institutional Trading of Compugen

A number of hedge funds have recently modified their holdings of the company. Rothschild Investment LLC bought a new position in Compugen in the second quarter worth $380,000. ARK Investment Management LLC lifted its holdings in shares of Compugen by 4.7% during the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company’s stock worth $1,850,000 after acquiring an additional 48,979 shares during the period. Squarepoint Ops LLC boosted its position in shares of Compugen by 23.4% during the 2nd quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 16,253 shares in the last quarter. Secure Asset Management LLC bought a new stake in Compugen in the second quarter valued at about $69,000. Finally, Joel Isaacson & Co. LLC raised its position in Compugen by 136.4% in the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 30,000 shares in the last quarter. Institutional investors own 12.22% of the company’s stock.

Compugen Stock Performance

Shares of NASDAQ:CGEN traded down $0.08 during midday trading on Friday, hitting $1.41. 441,994 shares of the stock were exchanged, compared to its average volume of 407,292. The company has a market capitalization of $125.82 million, a PE ratio of 70.50 and a beta of 2.64. The business’s fifty day simple moving average is $1.75 and its two-hundred day simple moving average is $1.87. Compugen has a 52-week low of $0.61 and a 52-week high of $3.03.

Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20). The firm had revenue of $17.13 million during the quarter, compared to the consensus estimate of $17.67 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%. During the same period in the prior year, the business earned ($0.11) EPS. As a group, equities analysts anticipate that Compugen will post 0.07 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.